A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by antidepressants and obesity medications.

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

British patients with obesity undergoing hip and knee replacements had less of a need for subsequent revision when, after surgery, they lost weight by using medications such as GLP-1 receptor agonists ...